{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=23",
    "query": {
      "intervention": "Blinded (placebo)",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 2208,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T01:39:02.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00883103",
      "title": "Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "2% Lidocaine jelly",
          "type": "DRUG"
        },
        {
          "name": "Plain aqueous gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baystate Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 137,
      "start_date": "2007-11",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2011-09-13",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "Springfield, Massachusetts",
      "locations": [
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00883103"
    },
    {
      "nct_id": "NCT02546570",
      "title": "Oxytocin and Affect Processing in Posttraumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Posttraumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-08",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2020-04-08",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546570"
    },
    {
      "nct_id": "NCT01545570",
      "title": "A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK2376497",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2011-11-07",
      "completion_date": "2012-12-23",
      "has_results": false,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545570"
    },
    {
      "nct_id": "NCT05754073",
      "title": "Oxytocin Effects on Bone in Children With Autism Spectrum Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Bone Health"
      ],
      "interventions": [
        {
          "name": "1. Intranasal oxytocin spray",
          "type": "DRUG"
        },
        {
          "name": "2. Intranasal placebo spray",
          "type": "DRUG"
        },
        {
          "name": "3. Intranasal Oxytocin spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elizabeth Austen Lawson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 96,
      "start_date": "2023-08-01",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05754073"
    },
    {
      "nct_id": "NCT03984812",
      "title": "Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3732394",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-06-17",
      "completion_date": "2020-03-23",
      "has_results": true,
      "last_update_posted_date": "2021-10-25",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984812"
    },
    {
      "nct_id": "NCT05306353",
      "title": "CD40L Antagonism in Rheumatoid Arthritis (RA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo for VIB4920",
          "type": "DRUG"
        },
        {
          "name": "VIB4920 with TNFi",
          "type": "DRUG"
        },
        {
          "name": "VIB4920 without TNFi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-07-25",
      "completion_date": "2025-07-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05306353"
    },
    {
      "nct_id": "NCT00808665",
      "title": "Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Spinal Fusion Acquired",
        "Spinal Stenosis",
        "Lesions of Lumbosacral Intervertebral Disc",
        "Spinal Diseases"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 68,
      "start_date": "2009-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00808665"
    },
    {
      "nct_id": "NCT02262026",
      "title": "The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "125 mg AZD0530",
          "type": "DRUG"
        },
        {
          "name": "50 mg AZD0530",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 49,
      "start_date": "2014-11-01",
      "completion_date": "2019-04-26",
      "has_results": false,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02262026"
    },
    {
      "nct_id": "NCT01121224",
      "title": "Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Saphenous Vein Graft Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Bare Metal Stent",
          "type": "DEVICE"
        },
        {
          "name": "Drug-Eluting Stent",
          "type": "DEVICE"
        },
        {
          "name": "Blinded clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Thienopyridine (open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 597,
      "start_date": "2012-01-11",
      "completion_date": "2016-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01121224"
    },
    {
      "nct_id": "NCT05285891",
      "title": "Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 123,
      "start_date": "2023-02-07",
      "completion_date": "2032-02-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-15T01:39:02.775Z",
      "location_count": 13,
      "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285891"
    }
  ]
}